<DOC>
	<DOCNO>NCT02318277</DOCNO>
	<brief_summary>The purpose study explore safety , tolerability , pharmacokinetics , immunogenicity preliminary efficacy INCB024360 administer combination MEDI4736 subject select advanced solid tumor .</brief_summary>
	<brief_title>A Study Epacadostat ( INCB024360 ) Combination With Durvalumab ( MEDI4736 ) Subjects With Selected Advanced Solid Tumors ( ECHO-203 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female subject , age 18 year old Histologically cytologically confirm diagnosis select locally advanced metastatic solid tumor Must fail least 1 prior treatment regimen locally advance metastatic disease intolerant treatment refuse standard treatment Laboratory medical history parameter within protocoldefined range Participation study receipt investigational study drug occur within 28 day 5 halflives ( whichever longer ) prior first dose Prior treatment immune checkpoint inhibitor ( eg , antiCTLA4 , antiPD1 , antiPDL1 , antibody drug specifically target Tcell costimulation ) IDO inhibitor ( exception tumor type PD1 pathway target agent approve , e.g . melanoma , nonsmall cell lung cancer . ) Receipt anticancer medication 21 day prior receive first dose study medication Has active inactive autoimmune process Evidence interstitial lung disease active , noninfectious pneumonitis Prior radiotherapy within 2 week initiate treatment ; Must recover radiationrelated toxicity , require corticosteroid , radiation pneumonitis Untreated central nervous system ( CNS ) metastases CNS metastasis progress Currently pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>